Mielke S

Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation.

Tobiasson M, Pandzic T, Illman J, ..., Dybedal I, Hellström-Lindberg E

J Clin Oncol 42 (12) 1378-1390 [2024-04-20; online 2024-01-17]

Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial

Bergman P, Blennow O, Hansson L, ..., Ljungman P, Aleman S

- - (-) - [2021-09-12; online 2021-09-12]